The GLP-1 Race: Who Will Dominate the Weight Loss Market?

The race is on for new weight loss medications based on GLP-1s to hit the market. This game changer is projected to grow significantly, potentially exceeding $126 billion by 2030.

As demand surges, companies are racing to develop new oral formulations of these medications, which are presently available only as injections. Industry leaders like Novo Nordisk and Eli Lilly are leading the charge. Novo Nordisk has already made strides with Rybelsus—a diabetes pill—and is now advancing another candidate, NN-9932. Meanwhile, Eli Lilly is gearing up to introduce orforglipron calcium, which is expected to hit the market by 2026.

With 63 different products currently in development, the competition intensifies as companies and other leading players strive to secure a larger slice of this lucrative market.